About
We are creating medical technology for the treatment of acute organ ischemia that reaches beyond the limits of anatomic engineering. We call it endovascular organ resuscitation. Our medical technology allows to perform metabolic engineering of the ischemic tissue through controlled modulation of its thermal energy. Our device delivers hypothermic protection to the organ in need, safely, quickly and controlled. Treatment will be based on real-time metabolic parameters. This isn't hibernation as perfected by nature. But it's as good as it gets for the ischemic organ. We believe in medicine that is personalized. Personalized medicine must be physiology-driven. To provide physiology-driven medicine means to provide real-time medicine. Therefore, we have to know the physiology, at all times.
Technologies
Keywords
Company Information
-
Employees 4
-
Founded 2006
-
Total Funding $4797289
Location
626 Rexcorp Plz, Uniondale, New York, United States, 11553
